Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Healthy male subjects 18-45 yrs old and 65 yrs or older inclusive and postmenopausal female 65 yrs or older

Exclusion Criteria:

• Women of childbearing potential

• Gastrointestinal disorders

• Bleeding disorders

• Peptic ulcer disease

• Abnormal ECG

• Abnormal Clinical laboratory tests

• Abnormal Thyroid

• Congestive heart failure

• Cholecystectomy

• Asthma

• Hypertension

• Inability to tolerate oral medication

• Inability to be venipunctured and/or tolerate venous access